The mission of TregTherapeutics, Inc is to provide resources to expedite development, and ultimately, the availability of next-generation therapeutics for the treatment of autoimmune and neurodegenerative disease.
The technology is multifaceted with several layers of complexity. First, there are two separate technologies, specified as “Vaccine Therapy” and “Adaptive Cell Therapy,” and each of these technologies has potential application to a range of disease states that share inflammation as a common denominator. Management has decided that its primary priority is to develop the Vaccine Therapy first. The vaccine approach defined by our platform technology is applicable to dozens of autoimmune diseases, as well as, numerous neurodegenerative diseases, but the roots of the technology are deeply embedded in the treatment and potential cure of multiple sclerosis. The company’s strategic plan recognizes that limited financial, technical, and time resources need to be focused and has developed a tactical plan to bring the technology into the clinic smoothly and quickly. That particular pathway can be discussed upon inquiry.
TregTherapeutics’ technical objectives, then, are clear. Human proof of concept studies have been formulated, and execution planned, for a representative autoimmune disease and for a selected neurodegenerative disease. Resources are being assembled to proceed toward a first in human study of both.
Financial resources are critical to the success of the enterprise. Availability of funding has an impact on our ability to proceed with planned activities, and acquiring the resources to enable execution of the chosen pathway is our highest priority. In addition to grant solicitation and other non-dilutive funding sources, we are also pursuing equity funding. We are engaged in a well-organized and orchestrated effort to establish an equity partnership with either angel investors, venture capital concerns, or appropriate pharmaceutical / biotech firms. This is a key strategic element of the TregTherapeutics plan. Interested investors are urged to contact us for further information.